Soligenix (Nasdaq:SNGX) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

SNGX 주식 개요

는 미국에서 희귀 질환을 치료하는 제품을 개발하고 상용화하는 데 주력하는 후기 단계의 바이오 제약 회사입니다.

SNGX 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	1/6
과거 실적	0/6
재무 상태	5/6
배당금	0/6

보상

수익은 연간 10.77% 증가할 것으로 예상됩니다.

지난 5년 동안 수입이 매년 3.8% 증가했습니다.

위험 분석

의미 있는 시가총액이 없습니다. ( $4M )

수익은 향후 3년간 연평균 14.9% 씩 감소할 것으로 예상됩니다.

지난 1년 동안 주주가 크게 희석되었습니다.

수익이 1백만 달러 미만인 경우 ( $699K )

+ 2 더 많은 위험

Soligenix, Inc. 경쟁사

Biocept

NasdaqCM:BIOC

US$2.7m

OpGen

NasdaqCM:OPGN

US$3.5m

Sonnet BioTherapeutics Holdings

NasdaqCM:SONN

US$2.9m

Azitra

NYSEAM:AZTR

US$2.7m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Soligenix
과거 주가
현재 주가	US$2.47
52주 최고치	US$32.00
52주 최저치	US$2.44
베타	1.93
11개월 변경	-50.99%
3개월 변경 사항	-68.18%
1년 변경 사항	-78.26%
33년 변화	-99.21%
5년 변화	-98.82%
IPO 이후 변화	-99.99%

최근 뉴스 및 업데이트

Recent updates

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

Oct 05

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Sep 12

Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Sep 17

Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Aug 30

Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

May 08

What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 16

Soligenix inks supply and distribution deal for SGX301 companion light device in cancer

Jan 07

Soligenix receives $1.5M grant advancing COVID-19 vaccine development

Dec 28

Soligenix's SGX942 flunks oral mucositis study in cancer patients, shares plummet 44%

Dec 22

Soligenix announces $20M strategic convertible debt financing agreement

Dec 16

주주 수익률

	SNGX	US Biotechs	US 마켓
7D	-6.8%	-1.9%	0.5%
1Y	-78.3%	10.4%	20.5%

수익률 대 산업: SNGX 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: SNGX 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is SNGX's price volatile compared to industry and market?
SNGX volatility
SNGX Average Weekly Movement	15.9%
Biotechs Industry Average Movement	10.3%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.2%
10% least volatile stocks in US Market	2.8%

안정적인 주가: SNGX 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: SNGX 의 주간 변동성은 지난 1년 동안 23% 에서 14% 로 감소했지만 여전히 US 주식의 75%보다 높습니다.

회사 소개

설립	직원	CEO	웹사이트
1987	14	Christopher Schaber	www.soligenix.com

는 후기 단계의 바이오 제약 회사로, 미국에서 희귀 질환 치료를 위한 제품 개발 및 상용화에 주력하고 있습니다. 이 회사는 특수 바이오 치료제 부문과 공중 보건 솔루션 부문으로 나뉘어 운영되고 있습니다. 특수 바이오 치료제 부문에서는 피부 T세포 림프종 치료를 위한 임상 3상 시험을 완료한 새로운 광역학 치료제인 SGX301(HyBryte)과 두경부암의 구강 점막염을 포함한 염증성 질환 치료를 위한 임상 3상 시험을 진행 중인 선천성 방어 조절 기술인 SGX942를 개발 중입니다; 중등도-중증 건선 치료를 위한 임상 2a상 연구 중인 IDR 기술인 SGX302; 베체트병의 아프타성 궤양 치료를 위한 임상 2a상 프로토콜인 SGX945 및 IDR 기술.

Soligenix, Inc. 기본 사항 요약

Soligenix 의 수익과 매출은 시가총액과 어떻게 비교하나요?
SNGX 기본 통계
시가총액	US$2.44m
수익(TTM)	-US$7.01m
수익(TTM)	US$699.21k

3.5x

P/S 비율

-0.3x

P/E 비율

SNGX 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
SNGX 손익 계산서(TTM)
수익	US$699.21k
수익 비용	US$633.04k
총 이익	US$66.17k
기타 비용	US$7.08m
수익	-US$7.01m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-7.10
총 마진	9.46%
순이익 마진	-1,002.55%
부채/자본 비율	389.9%

SNGX 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

SNGX 주식 개요

보상

위험 분석

Soligenix, Inc. 경쟁사

NasdaqCM:BIOC

US$2.7m

NasdaqCM:OPGN

US$3.5m

NasdaqCM:SONN

US$2.9m

NYSEAM:AZTR

US$2.7m

가격 내역 및 성능

최근 뉴스 및 업데이트

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Consensus revenue estimates decrease by 13%, EPS upgraded

Price target decreased by 29% to US$2.50

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Soligenix, Inc., Annual General Meeting, May 23, 2024

Recent updates

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Consensus revenue estimates decrease by 13%, EPS upgraded

Price target decreased by 29% to US$2.50

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Consensus EPS estimates upgraded to US$0.63 loss

Price target increased by 7.7% to US$3.50

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Consensus revenue estimates decrease by 11%, EPS upgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

New major risk - Share price stability

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Consensus EPS estimates upgraded to US$0.83 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 35% to US$3.25

Insufficient new directors

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Consensus revenue estimates increase by 13%

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

No longer forecast to breakeven

Consensus revenue estimates decrease by 76%, EPS upgraded

No longer forecast to breakeven

Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Publication Demonstrating Positive Correlates of Protection with Rivax® in Non-Human Primate Survival After Ricin Challenge

Soligenix, Inc. Initiates Phase 2 Clinical Trial of SGX302 (Synthetic Hypericin) for the Treatment of Mild-To-Moderate Psoriasis

Soligenix Announces Submission of New Drug Application to the FDA for Hybryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Receives Non Compliance Notice from Nasdaq

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Soligenix, Inc. Announces U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix announces $2.6M FDA grant to further study blood cancer candidate

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M

Soligenix, Inc., Annual General Meeting, Sep 22, 2022

Soligenix, Inc. Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, SERB Pharma team up to develop therapy for ricin poisoning

Soligenix, Inc. Announces HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in Treatment of Psoriasis

Soligenix Announces Successful Protection Using A Bivalent Thermostabilized Filovirus Vaccine

Soligenix Receives US Patent Allowance for Its Thermostabilized Vaccine Platform

Price target decreased to US$3.88